Amgen reported a 4% increase in total revenues to $6.7 billion for the third quarter of 2021, driven by higher unit demand. GAAP EPS decreased 3% to $3.31, while non-GAAP EPS increased 11% to $4.67. The company generated $2.2 billion in free cash flow.
Total revenues increased 4% to $6.7 billion, driven by higher unit demand.
GAAP EPS decreased 3% to $3.31, impacted by a licensing-related expense.
Non-GAAP EPS increased 11% to $4.67, driven by increased revenues.
Generated $2.2 billion of free cash flow, influenced by COVID-19 related payment terms in the prior year.
Amgen provided full year 2021 guidance, expecting total revenues in the range of $25.8 billion to $26.2 billion, GAAP EPS in the range of $9.55 to $10.21, and non-GAAP EPS in the range of $16.50 to $17.10.
Visualization of income flow from segment revenue to net income